Mandate

Vinge advises Tele2 in the merger with Com Hem

Tele2 AB (publ) and Com Hem Holding AB (publ) announced on 10 January 2018 that they have agreed on a combination through a statutory merger in accordance with the Swedish Companies Act.

The combined company will be a leading integrated connectivity provider by combining an award-winning mobile network with the fastest national fixed network and the widest range of content in the market. The combination is conditional upon, inter alia, approval from the relevant competition authorities and approval of the merger from the shareholders in Tele2 and Com Hem. The merger is currently expected to be completed in the second half of 2018.

Vinge’s team primarily consists of Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Amanda Knutsson and Annika Nyberg Ekenberg (capital markets), Marcus Glader, Johan Karlsson, Emma Johansson, Grant McKelvey and Sebastian Örndahl (competition and regulatory), Louise Brorsson Salomon, Helena Håkansson and Lionardo Ojeda (financing) as well as Fredrik Dahl and Fredrik Gustafsson (employment).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026